|
1
|
Laguillaumie MO, Lewuillon C, Touil Y, Lemonnier L, Idziorek T. [Lethal AML? Calcium signalling to the rescue!]. Med Sci (Paris) 2023; 39:515-521. [PMID: 37387659 DOI: 10.1051/medsci/2023083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/01/2023] Open
Abstract
Acute myeloid leukemia (AML) is characterized by genetic aberrations in hematopoietic precursors of the myeloid lineage which lead to their defective maturation/function. While intensive chemotherapy protocols result in complete remission in 50 % to 80 % of AML patients, relapse occurs in the majority of cases. While calcium signalling is a well-known contributor to cancer hallmarks, few AML related studies have focused on relevant calcium targets. Our purpose here is to highlight calcium channels and associated signalling pathways involved in AML, in order to promote the development of treatments specifically targeting these pathways.
Collapse
Affiliation(s)
- Marie-Océane Laguillaumie
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Clara Lewuillon
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Yasmine Touil
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Loïc Lemonnier
- Univ. Lille, Inserm, U1003 - PHYCEL - physiologie cellulaire, F-59000 Lille, France - Univ. Lille, laboratoire d'excellence, Ion Channels Science and Therapeutics, F-59655 Villeneuve d'Ascq, France
| | - Thierry Idziorek
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| |
Collapse
|
|
2
|
Lewuillon C, Guillemette A, Titah S, Shaik FA, Jouy N, Labiad O, Farfariello V, Laguillaumie MO, Idziorek T, Barthélémy A, Peyrouze P, Berthon C, Tarhan MC, Cheok M, Quesnel B, Lemonnier L, Touil Y. Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure. Int J Mol Sci 2022; 23:ijms23105555. [PMID: 35628366 PMCID: PMC9141756 DOI: 10.3390/ijms23105555] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 05/11/2022] [Accepted: 05/13/2022] [Indexed: 12/19/2022] Open
Abstract
Acute myeloid leukemia (AML) is a hematological malignancy with a high risk of relapse. This issue is associated with the development of mechanisms leading to drug resistance that are not yet fully understood. In this context, we previously showed the clinical significance of the ATP binding cassette subfamily B-member 1 (ABCB1) in AML patients, namely its association with stemness markers and an overall worth prognosis. Calcium signaling dysregulations affect numerous cellular functions and are associated with the development of the hallmarks of cancer. However, in AML, calcium-dependent signaling pathways remain poorly investigated. With this study, we show the involvement of the ORAI1 calcium channel in store-operated calcium entry (SOCE), the main calcium entry pathway in non-excitable cells, in two representative human AML cell lines (KG1 and U937) and in primary cells isolated from patients. Moreover, our data suggest that in these models, SOCE varies according to the differentiation status, ABCB1 activity level and leukemic stem cell (LSC) proportion. Finally, we present evidence that ORAI1 expression and SOCE amplitude are modulated during the establishment of an apoptosis resistance phenotype elicited by the chemotherapeutic drug Ara-C. Our results therefore suggest ORAI1/SOCE as potential markers of AML progression and drug resistance apparition.
Collapse
Affiliation(s)
- Clara Lewuillon
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Aurélie Guillemette
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Sofia Titah
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Faruk Azam Shaik
- Institut de Recherche sur le Cancer de Lille (IRCL), F-59000 Lille, France;
- LIMMS/CNRS-IIS IRL2820, The University of Tokyo, Tokyo 153-8505, Japan;
| | - Nathalie Jouy
- UMS 2014/US41 Plateformes Lilloises En Biologie Et Sante, Université de Lille, F-59000 Lille, France;
| | - Ossama Labiad
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Valerio Farfariello
- Inserm, U1003-PHYCEL-Physiologie Cellulaire, Université de Lille, F-59000 Lille, France;
- Laboratory of Excellence, Ion Channels Science and Therapeutics, Université de Lille, F-59655 Villeneuve d’Ascq, France
| | - Marie-Océane Laguillaumie
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Thierry Idziorek
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Adeline Barthélémy
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Pauline Peyrouze
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Céline Berthon
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Mehmet Cagatay Tarhan
- LIMMS/CNRS-IIS IRL2820, The University of Tokyo, Tokyo 153-8505, Japan;
- CNRS, Centrale Lille, Junia, Université Polytechnique Hauts-de-France, UMR 8520—IEMN—Institut d’Electronique de Microélectronique et de Nanotechnologie, Université de Lille, F-59000 Lille, France
| | - Meyling Cheok
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Bruno Quesnel
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Loïc Lemonnier
- Inserm, U1003-PHYCEL-Physiologie Cellulaire, Université de Lille, F-59000 Lille, France;
- Laboratory of Excellence, Ion Channels Science and Therapeutics, Université de Lille, F-59655 Villeneuve d’Ascq, France
- Correspondence: loï (L.L.); (Y.T.)
| | - Yasmine Touil
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
- Correspondence: loï (L.L.); (Y.T.)
| |
Collapse
|
|
3
|
Lewuillon C, Laguillaumie MO, Quesnel B, Idziorek T, Touil Y, Lemonnier L. Put in a “Ca2+ll” to Acute Myeloid Leukemia. Cells 2022; 11:cells11030543. [PMID: 35159351 PMCID: PMC8834247 DOI: 10.3390/cells11030543] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 01/28/2022] [Accepted: 02/01/2022] [Indexed: 02/05/2023] Open
Abstract
Acute myeloid leukemia (AML) is a clonal disorder characterized by genetic aberrations in myeloid primitive cells (blasts) which lead to their defective maturation/function and their proliferation in the bone marrow (BM) and blood of affected individuals. Current intensive chemotherapy protocols result in complete remission in 50% to 80% of AML patients depending on their age and the AML type involved. While alterations in calcium signaling have been extensively studied in solid tumors, little is known about the role of calcium in most hematologic malignancies, including AML. Our purpose with this review is to raise awareness about this issue and to present (i) the role of calcium signaling in AML cell proliferation and differentiation and in the quiescence of hematopoietic stem cells; (ii) the interplay between mitochondria, metabolism, and oxidative stress; (iii) the effect of the BM microenvironment on AML cell fate; and finally (iv) the mechanism by which chemotherapeutic treatments modify calcium homeostasis in AML cells.
Collapse
Affiliation(s)
- Clara Lewuillon
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; (C.L.); (M.-O.L.); (B.Q.); (T.I.); (Y.T.)
| | - Marie-Océane Laguillaumie
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; (C.L.); (M.-O.L.); (B.Q.); (T.I.); (Y.T.)
| | - Bruno Quesnel
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; (C.L.); (M.-O.L.); (B.Q.); (T.I.); (Y.T.)
| | - Thierry Idziorek
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; (C.L.); (M.-O.L.); (B.Q.); (T.I.); (Y.T.)
| | - Yasmine Touil
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; (C.L.); (M.-O.L.); (B.Q.); (T.I.); (Y.T.)
| | - Loïc Lemonnier
- Univ. Lille, Inserm, U1003—PHYCEL—Physiologie Cellulaire, F-59000 Lille, France
- Laboratory of Excellence, Ion Channels Science and Therapeutics, F-59655 Villeneuve d’Ascq, France
- Correspondence:
| |
Collapse
|